Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Kane Biotech Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by BurconNutriFanon Sep 29, 2016 12:51am
92 Views
Post# 25289263

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:News release - end of joint development with pharma firm

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:News release - end of joint development with pharma firmIt is interesting that a psychopath like BT has been preaching that the stock is going down below $.03 for half a year like he is some kind of expert. Turns out he bought at $.12 which is at least 5 times what he says the stock will be, so the expert wasn't very good at predictions back then but somehow feels after blowing it that he is now an expert. 

For anyone intelligent reading this board the money raised is used for marketing and trials but Bt is crying because he wants instant news on the trials. Big pharma took over 2 years to finish their trials. Some trials haven't even started but Bt wants the results now.

Does anyone here want me to sick KNE's lawyers on him and stick him with a few thousand $ bill? I'm thinking the psychopath deserves it.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities